The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report

References

• AthyrosVGGanotakisESElisafMSLiberopoulosENGoudevenosIAKaragiannisAGREECE-METS Collaborative GroupPrevalence of vascular disease in metabolic syndrome using three proposed definitionsInt J Cardiol200711720421016854482
   PubMed Web of Science ®Google Scholar
• DaskalopoulouSSAthyrosVGKolovouGDAnagnostopoulouKKMikhailidisDPDefinitions of metabolic syndrome: Where are we now?Curr Vasc Pharmacol20064318519716842136
   PubMedGoogle Scholar
• de SimoneGDevereuxRBChinaliMStrong Heart Study InvestigatorsPrognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart StudyDiabetes Care20073071851185617440172
   PubMed Web of Science ®Google Scholar
• DekkerJMGirmanCRhodesTMetabolic syndrome and 10-year cardiovascular disease risk in the Hoorn StudyCirculation2005112566667316061755
   PubMed Web of Science ®Google Scholar
• GamiASWittBJHowardDEMetabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studiesJ Am Coll Cardiol200749440341417258085
   PubMed Web of Science ®Google Scholar
• FerrarioCMMooreMABestermannWJrCOSEHC global vascular risk management quality improvement program: rationale and designVasc Health Risk Manag201061135114521931496
   PubMedGoogle Scholar
• BestermannWHoustonMCBasileJAddressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndromeAm J Med Sci2005329629230515958871
   PubMed Web of Science ®Google Scholar
• EganBMLacklandDTIgho-PemuPCardiovascular risk factor control in communities – update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians’ NetworkJ Clin Hypertens (Greenwich)200681287988617170614
   PubMedGoogle Scholar
• FerrarioCMHighlights of the Tenth Annual COSEHC National Scientific SessionAm J Med Sci2004327523423515166740
   PubMedGoogle Scholar
• FerrarioCMCOSEHC overviewAm J Med Sci2004327523315166739
   PubMedGoogle Scholar
• FerrarioCMHighlights of the Twelfth Annual COSEHC National Scientific SessionAm J Med Sci200633125916479176
   PubMedGoogle Scholar
• HallWDFerrarioCMMooreMAHypertension-related morbidity and mortality in the southeastern United StatesAm J Med Sci199731341952099099149
   PubMed Web of Science ®Google Scholar
• HoustonMCBasileJBestermannWHAddressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United StatesAm J Med Sci2005329627629115958870
   PubMed Web of Science ®Google Scholar
• JonesDBasileJCushmanWManaging hypertension in the southeastern United States: applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)Am J Med Sci1999318635736410616159
   PubMed Web of Science ®Google Scholar
• LacklandDTBendallHEOsmondCEganBMBarkerDJLow birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United StatesArch Intern Med2000160101472147610826460
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRNational Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational High Blood Pressure Education Program Coordinating CommitteeThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• GoASMozaffarianDRogerVLAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeExecutive summary: heart disease and stroke statistics – 2013 update: a report from the American Heart AssociationCirculation2013127114315223283859
   PubMed Web of Science ®Google Scholar
• HowardVJWoolsonRFEganBMPrevalence of hypertension by duration and age at exposure to the stroke beltJ Am Soc Hypertens201041324120374949
   PubMed Web of Science ®Google Scholar
• LacklandDTEganBMThe dominant role of systolic hypertension as a vascular risk factor: evidence from the southeastern United StatesAm J Med Sci1999318636536810616160
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators; BodenWEProbstfieldJLAndersonTThe role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH)Am Heart J2011161347147721392600
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators; BodenWEProbstfieldJLAndersonTNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMedGoogle Scholar
• DehghanMMenteATeoKKRelationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countriesCirculation2012126232705271223212996
   PubMed Web of Science ®Google Scholar
• MichosEDSibleyCTBaerJTBlahaMJBlumenthalRSNiacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trialsJ Am Coll Cardiol201259232058206422520249
   PubMed Web of Science ®Google Scholar
• TeoKYusufSSleightPONTARGET/TRANSCEND InvestigatorsRationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trialsAm Heart J20041481526115215792
   PubMed Web of Science ®Google Scholar
• TeoKKMitchellLBPogueJBoschJDagenaisGYusufSHOPE InvestigatorsEffect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunctionCirculation20041101413141715353497
   PubMed Web of Science ®Google Scholar
• McQueenMJKavsakPAXuLShestakovskaOYusufSPredicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable populationClin Biochem2013461–25923063983
   PubMed Web of Science ®Google Scholar
• ONTARGET Investigators; YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLPRoFESS Study GroupTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• BasileJHoustonMFerrarioCIncremental risk-factor reduction improves overall cardiovascular benefit: is it time to abandon the silos?J Clin Hypertens (Greenwich)200681068668817028480
   PubMedGoogle Scholar
• GueyffierFBoutitieFBoisselJPEffect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA InvestigatorsAnn Intern Med1997126107617679148648
   PubMed Web of Science ®Google Scholar
• JonesCANagpalSAn update: women, hypertension and therapeutic efficacyCan J Cardiol200117121283128911773939
   PubMed Web of Science ®Google Scholar
• QuanAKerlikowskeKGueyffierFBoisselJPINDANA investigatorsPharmacotherapy for hypertension in women of different racesCochrane Database Syst Rev20003CD00214610908526
   PubMedGoogle Scholar
• ManciaGGrassiGAntihypertensive treatment: past, present and futureJ Hypertens Suppl1998161S1S79534090
   PubMedGoogle Scholar
• ZanchettiAManciaGBlackHRFacts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertensionJ Hypertens200927467367919516168
   PubMed Web of Science ®Google Scholar
• ZanchettiAGrassiGManciaGWhen should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisalJ Hypertens200927592393419381107
   PubMed Web of Science ®Google Scholar
• BestermannWHLacklandDTRiehleJEEganBMA systematic approach to managing hypertension and the metabolic syndrome in primary careSouth Med J2004971093293815558916
   PubMed Web of Science ®Google Scholar
• ManciaGOmboniSParatiGThe importance of blood pressure variability in hypertensionBlood Press Monit20005Suppl 1S9S1510904237
   PubMedGoogle Scholar
• ManciaGGrassiGSystolic and diastolic blood pressure control in antihypertensive drug trialsJ Hypertens20022081461146412172300
   PubMed Web of Science ®Google Scholar
• ManciaGDefining blood pressure goals: is it enough to manage total cardiovascular risk?J Hypertens Suppl2009275S3S819587552
   PubMedGoogle Scholar
• BasileJBlood pressure responder rates versus goal rates: which metric matters?Ther Adv Cardiovasc Dis20093215717419299428
   PubMedGoogle Scholar
• KranjcecDAltabasVMetabolic syndrome influencing infarct size and heart failure in patients with acute coronary syndrome: does gender matter?Endocr J201259121065107622971940
   PubMed Web of Science ®Google Scholar
• PocockSJMcCormackVGueyffierFBoutitieFFagardRHBoisselJPA score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trialsBMJ20013237304758111451781
   PubMedGoogle Scholar
• SchlendorfKHNasirKBlumenthalRSLimitations of the Framingham risk score are now much clearerPrev Med200948211511619124038
   PubMed Web of Science ®Google Scholar
• GueyffierFBoutitieFBoisselJPINDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary resultsTherapie19955043533627482389
   PubMedGoogle Scholar
• GueyffierFBoisselJPBoutitieFEffect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project CollaboratorsStroke19972812255725629412649
   PubMedGoogle Scholar
• GueyffierFBulpittCBoisselJPAntihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA GroupLancet1999353915579379610459960
   PubMed Web of Science ®Google Scholar
• LiWGueyffierFBoisselJPGirardPBoutitieFCucheratM[Identification and prediction of responders to a therapy. A model and its preliminary application to hypertension.]Arch Mal Coeur Vaiss199891810591063 French [with English abstract]9749165
   PubMedGoogle Scholar
• LièvreMGueyffierFEkbomTEfficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering CommitteeDiabetes Care200023Suppl 2B65B7110860193
   PubMedGoogle Scholar
• MatsumotoMCerebrovascular disease: [Impact of INDANA meta-analysis and PROGRESS trial.]Nippon Rinsho200462Suppl 3605611 Japanese15179938
   PubMedGoogle Scholar